Lake Hills Wealth Management LLC Buys Shares of 3,112 Natera, Inc. (NASDAQ:NTRA)

Lake Hills Wealth Management LLC bought a new stake in Natera, Inc. (NASDAQ:NTRA) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 3,112 shares of the medical research company’s stock, valued at approximately $440,000. Natera comprises about 0.3% of Lake Hills Wealth Management LLC’s holdings, making the stock its 27th biggest position.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. LRI Investments LLC acquired a new stake in shares of Natera during the 4th quarter worth approximately $29,000. Blue Trust Inc. grew its holdings in shares of Natera by 104.3% during the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock worth $30,000 after purchasing an additional 97 shares in the last quarter. EverSource Wealth Advisors LLC grew its holdings in shares of Natera by 372.9% during the 4th quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company’s stock worth $52,000 after purchasing an additional 261 shares in the last quarter. Principal Securities Inc. grew its holdings in shares of Natera by 20.7% during the 4th quarter. Principal Securities Inc. now owns 344 shares of the medical research company’s stock worth $54,000 after purchasing an additional 59 shares in the last quarter. Finally, Steward Partners Investment Advisory LLC grew its holdings in shares of Natera by 1,328.0% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 357 shares of the medical research company’s stock worth $57,000 after purchasing an additional 332 shares in the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the company. UBS Group lifted their price objective on Natera from $211.00 to $218.00 and gave the stock a “buy” rating in a report on Friday, May 9th. Robert W. Baird raised their target price on Natera from $183.00 to $188.00 and gave the stock an “outperform” rating in a research report on Friday, February 28th. Piper Sandler raised their target price on Natera from $205.00 to $210.00 and gave the stock an “overweight” rating in a research report on Thursday, May 15th. Royal Bank of Canada assumed coverage on Natera in a research report on Thursday, March 13th. They set an “outperform” rating and a $251.00 target price for the company. Finally, BTIG Research restated a “buy” rating on shares of Natera in a research report on Friday, February 28th. One equities research analyst has rated the stock with a sell rating and fifteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $184.63.

Insider Buying and Selling at Natera

In other news, Director Gail Boxer Marcus sold 4,000 shares of the business’s stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $147.69, for a total transaction of $590,760.00. Following the completion of the sale, the director now owns 9,704 shares in the company, valued at $1,433,183.76. The trade was a 29.19% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Steven Leonard Chapman sold 6,702 shares of the business’s stock in a transaction on Monday, March 17th. The stock was sold at an average price of $146.03, for a total value of $978,693.06. Following the sale, the chief executive officer now owns 203,354 shares of the company’s stock, valued at approximately $29,695,784.62. The trade was a 3.19% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 68,275 shares of company stock worth $10,075,783. 7.60% of the stock is currently owned by insiders.

Natera Trading Down 1.1%

Shares of NTRA opened at $163.76 on Friday. The stock has a fifty day moving average price of $151.77 and a two-hundred day moving average price of $158.67. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. Natera, Inc. has a 52-week low of $92.14 and a 52-week high of $183.00. The company has a market cap of $22.36 billion, a price-to-earnings ratio of -93.05 and a beta of 1.74.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Thursday, May 8th. The medical research company reported ($0.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.59) by $0.09. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The firm had revenue of $501.83 million during the quarter, compared to the consensus estimate of $446.68 million. During the same quarter in the previous year, the company posted ($0.56) EPS. The business’s revenue for the quarter was up 36.5% compared to the same quarter last year. Analysts predict that Natera, Inc. will post -1.49 EPS for the current fiscal year.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.